Carrick Therapeutics Entered into a Clinical Trial Collaboration and Supply Agreement with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant
Shots:
- The companies collaborated to evaluate Carrick’s samuraciclib (CT7001) + Arvinas’ vepdegestrant (PROTAC estrogen receptor protein degrader) being developed in collaboration with Pfizer in the P-Ib/II trial for ER+, HER2- metastatic breast cancer who received prior CDK4/6i
- Arvinas will be the regulatory sponsor of the study in the US while Pfizer will be the acting sponsor for the study conducted in the US, as well as the regulatory & acting sponsor outside of the US. The trial is expected to be initiated in H2’23
- Arvinas & Pfizer collaborated in July 2021 for the co-development & co-commercialization of vepdegestrant where both companies equally share development costs, commercialization expenses, and profits
Ref: Globenewswire | Image: Carrick Therapeutics
Related News:- Pfizer Reports P-III Study (BENEGENE-2) Results of Fidanacogene Elaparvovec for Hemophilia B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
